PRESS RELEASES

Date Title and Summary View
Toggle Summary IAVI, GlycoMimetics, and Glycosensors and Diagnostics Collaborate to Develop Novel AIDS Vaccine Candidate
IAVI, GlycoMimetics, and Glycosensors and Diagnostics Collaborate to Develop Novel AIDS Vaccine Candidate NEW YORK, NY, GAITHERSBURG, MD, and ATHENS, GA, May 9, 2012 – The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, Inc. (GMI), and Glycosensors and Diagnostics, LLC
View HTML
Toggle Summary GlycoMimetics Announces Two Key Leadership Promotions
— Helen Thackray, M.D., Appointed Chief Medical Officer; Brian Hahn Named Chief Financial Officer —
View HTML
Toggle Summary Progress of GlycoMimetics' Novel Compounds Highlighted at 2011 Annual Meeting of the American Society of Hematology View HTML
Toggle Summary GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients Experiencing Vaso-occlusive Crisis Associated with Sickle Cell Disease View HTML
Toggle Summary GlycoMimetics Announces Data Presentations on Lead Compound at American Society of Hematology Annual Meeting View HTML
Toggle Summary Blood Publishes Pre-Clinical Data on GlycoMimetics, Inc. Lead Compound in Sickle Cell Disease Model View HTML
Toggle Summary Key GlycoMimetics Patents Issue in the U.S. View HTML
Toggle Summary GlycoMimetics Initiates Phase 2 Clinical Trial of Lead Candidate GMI-1070 in Sickle Cell Patients View HTML
Toggle Summary GlycoMimetics Announces Two Oral Presentations on Lead Drug Candidate GMI-1070 at American Society of Hematology Annual Meeting View HTML
Toggle Summary GlycoMimetics, Inc. Attracts $38 Million in Latest Venture Round View HTML